ClinicalTrials.gg
RecruitingNCT05942456Updated May 14, 2024

Soluble B7-H3 as a Biomarker for Osteosarcoma

An observational study in Biomarker, Progression and Osteosarcoma, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Peking University People's Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
12 Years and older
Sex
All
01

Study summary

Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment.

02

Conditions studied

  • Biomarker
  • Progression
  • Osteosarcoma
  • Surveillance

Keywords

  • sB7-H3
  • osteosarcoma
  • biomarker
  • prognosis
  • clinical evaluation
03

In context

Disease Progression

403 studies on the registry are indexed under Disease Progression; 112 are open to participants now.

This study's planned enrollment of 200 is close to the median of 200 across 213 observational studies indexed under Disease Progression.

Browse Disease Progression studies →

Lead sponsor

Peking University People's Hospital is the lead sponsor of 611 studies on the registry; 248 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Initial treated osteosarcoma patients in PKUPH and later would recieve definitive surgery in PKUPH with complete clinical materials.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • High Grade osteosarcoma verified with pathologic diagnosis.
  • systemic treatment-naive before the first time Blood drawing.
  • 0 or 1 and all the other imagings indicate that patients could tolerate standard PKUPH-OS-02 protocol chemotherapy.
  • All radiographs are complete for clinical evaluation.

Exclusion criteria

Exclusion Criteria:

  • Patients who Can't tolerate blood drawing.
  • Patients without complete medical records in PKUPH system.
  • Patients who can't tolerate PKUPH-OS-02 chemotherapy.
  • other conditions that investigators think are not suitable for this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • sB7-H3 of treatment-naive osteosarcoma patients

    Before delivering neoadjuvant chemotherapy, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood

    Diagnostic Test: ELISA: enzyme-linked immunosorbent assay

  • sB7-H3 after neoadjuvant chemotherapy for osteosarcoma patients

    After neoadjuvant chemotherapy and before definitive surgery, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood

    Diagnostic Test: ELISA: enzyme-linked immunosorbent assay

Interventions

  • Diagnostic testELISA: enzyme-linked immunosorbent assay

    enzyme-linked immunosorbent assay

06

What researchers measure

Primary outcomes

  1. correlation of quantity of Protein B7-H3 Expression with clinical evaluation

    Clinical evaluation according to RECIST 1.1

    Time frame: 6 months

Secondary outcomes

  1. correlation of quantity of Protein B7-H3 Expression with histological responses

    Histological responses according to Huvos Grade

    Time frame: 6 months

  2. correlation of quantity of Protein B7-H3 Expression with event-free survival

    event-free survival calculated from starting systemic therapy to any tumor-related events for progression

    Time frame: 2 years

  3. correlation of quantity of Protein B7-H3 Expression with overall survival

    overall survival calculated from starting systemic therapy to death

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wang L, Kang FB, Zhang GC, Wang J, Xie MF, Zhang YZ. Clinical significance of serum soluble B7-H3 in patients with osteosarcoma. Cancer Cell Int. 2018 Aug 13;18:115. doi: 10.1186/s12935-018-0614-z. eCollection 2018. PubMed 30123093 ↗
  • Xie L, Chen C, Liang X, Xu J, Sun X, Sun K, Yang R, Tang X, Guo W. Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy. Orthop Surg. 2023 Mar;15(3):829-838. doi: 10.1111/os.13620. Epub 2022 Dec 15. PubMed 36519392 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jul 2024, 12 months after the start.

Of 103 non-industry observational studies under Disease Progression, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 153. This study's planned 12 months is below that.

Counting every sponsor, half of 108 studies reached it within 68 months; a quarter within 35 and three quarters within 153.

Disease Progression covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2023
First posted
Jul 12, 2023
StartActual
Jun 5, 2023
Primary completionEst.
Jul 1, 2024
CompletionEst.
Dec 31, 2024
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05942456
Responsible party
Xie Lu (Musculoskeletal Tumor Center, Peking University People's Hospital) — Principal investigator
First posted
Jul 12, 2023
Start date
Jun 5, 2023
Primary completion
Jul 1, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
May 14, 2024

Study contacts

Lu Xie, M.D.
Contact
xie.lu@hotmail.com
+86-13401044719

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion